Kaleido Biosciences Reports Second Quarter 2021 Financial Results
Kaleido Biosciences (Nasdaq: KLDO) reported a net loss of $23.9 million, or $0.56 per share, for Q2 2021, an increase from $18.9 million in Q2 2020. R&D expenses rose to $17.6 million due to increased clinical material production. The company plans to report topline data from a study of KB295 for ulcerative colitis by Q3 end and collaborate with the COPD Foundation on a Phase 2 study of KB109, targeting COPD patients in Q1 2022. Cash reserves stand at $72 million, with a runway into Q2 2022.
- Cash and cash equivalents of $72 million provide operational runway into Q2 2022.
- Collaboration with the COPD Foundation to enhance development of KB109 for COPD.
- Net loss increased to $23.9 million in Q2 2021 from $18.9 million in Q2 2020.
- R&D expenses rose significantly to $17.6 million, indicating increased costs without immediate revenue impact.
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter--
--Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical study in first quarter 2022--
--Additional data from an observational clinical study of KB109 in patients with mild-to-moderate COVID-19 expected by end of third quarter--
LEXINGTON, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today reported financial results for the second quarter ended June 30, 2021.
“We have made considerable progress so far this year across our dynamic and diverse clinical pipeline of novel, targeted Microbiome Metabolic TherapyTM (MMT) candidates. We continue to advance KB295 in patients with mild-to-moderate ulcerative colitis and anticipate reporting topline data from the clinical study by the end of the third quarter,” said Dan Menichella, President and Chief Executive Officer of Kaleido. “This quarter, we also expect to report data from the observational clinical study evaluating COVID-19 symptoms in 'Long Hauler’ patients that participated in our prior COVID-19 clinical studies.”
Continued Mr. Menichella: “Additionally, we are proud to have announced a strategic collaboration with the COPD Foundation, an organization uniquely qualified to aid us in our mission to improve the lives of patients suffering from COPD. Our KB109 program will be greatly enhanced with support from the COPD Foundation, and we look forward to a productive and mutually beneficial partnership that leverages the strong data from our COVID-19 studies to explore treatment of COPD, the most prevalent chronic respiratory illness, impacting over 250 million people worldwide. While we are prioritizing COPD based on our assessment of the unmet need and commercial opportunity, we will continue to evaluate development opportunities for KB109 in COVID-19 with partners and government agencies.”
Recent Program and Corporate Highlights
- Topline data from the non-IND clinical study of KB295 in patients with mild-to-moderate ulcerative colitis (UC) are expected by the end of the third quarter.
- Additional data from the observational clinical study of KB109 in patients with mild-to-moderate COVID-19 are expected by the end of the third quarter.
- In August, Kaleido announced a collaboration with the COPD Foundation that is on track to initiate a Phase 2 clinical study of KB109 in patients with chronic obstructive pulmonary disease (COPD) in the first quarter of 2022.
Second Quarter Financial Results
Kaleido reported a net loss of
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
As of June 30, 2021, the Company reported cash and cash equivalents of
About Microbiome Metabolic Therapies (MMT™)
Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates rapidly into clinical studies in healthy subjects and patients. These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the Company conducts clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., and in Phase 2 or later development.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of initiation, completion and reporting of results of clinical studies, and our anticipated regulatory filings, strategy, business plans and focus. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering and those risks more fully discussed in the section entitled "Risk Factors" in Kaleido’s annual report on Form 10-K for the fiscal year ended December 31, 2020, which is available at www.sec.gov, as well as discussions of potential risks, uncertainties, and other important factors in Kaleido’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Kaleido’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Kaleido undertakes no duty to update this information unless required by law.
Kaleido Biosciences, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations (Unaudited)
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| Revenue: | |||||||||||||||||
| Collaboration revenue | $ | 211 | $ | 250 | $ | 508 | $ | 250 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 17,633 | 12,833 | 34,818 | 25,970 | |||||||||||||
| General and administrative | 5,785 | 5,559 | 11,245 | 11,476 | |||||||||||||
| Total operating expenses | 23,418 | 18,392 | 46,063 | 37,446 | |||||||||||||
| Loss from Operations | (23,207 | ) | (18,142 | ) | (45,555 | ) | (37,196 | ) | |||||||||
| Other (expense) income, net | (682 | ) | (780 | ) | (1,376 | ) | (1,277 | ) | |||||||||
| Net loss | $ | (23,889 | ) | $ | (18,922 | ) | $ | (46,931 | ) | $ | (38,473 | ) | |||||
| Net loss per share—basic and diluted | $ | (0.56 | ) | $ | (0.59 | ) | $ | (1.14 | ) | $ | (1.24 | ) | |||||
| Weighted-average common shares outstanding—basic and diluted | 42,538,563 | 31,880,672 | 41,123,435 | 31,106,977 | |||||||||||||
Kaleido Biosciences, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet Data (Unaudited)
(in thousands)
| June 30, 2021 | December 31, 2020 | |||||||
| Assets: | ||||||||
| Cash and cash equivalents | $ | 71,979 | $ | 46,222 | ||||
| Other assets | 12,311 | 13,122 | ||||||
| Total assets | $ | 84,290 | $ | 59,344 | ||||
| Liabilities and stockholders' equity | ||||||||
| Liabilities | $ | 34,024 | $ | 38,848 | ||||
| Stockholders' equity | 50,266 | 20,496 | ||||||
| Total liabilities and stockholders' equity | $ | 84,290 | $ | 59,344 | ||||
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com
FAQ
What were Kaleido Biosciences' earnings for Q2 2021?
What are Kaleido's future clinical study plans?
How much cash does Kaleido Biosciences currently have?
What is the financial outlook for Kaleido Biosciences?
